期刊
BRITISH JOURNAL OF PHARMACOLOGY
卷 171, 期 6, 页码 1420-1434出版社
WILEY
DOI: 10.1111/bph.12500
关键词
Acyl amide; cannabinoid; fatty acid amino hydrolase; neurodevelopment; prenatal exposure
资金
- NIH [DA029381, HD065561, NS048884, DA011322, DA021696, DA032150]
- BCM IDDRC from the Eunice Kennedy Shriver NICHD [P30HD024064]
Background and PurposeFatty acid amide hydrolase inhibitors show promise as a treatment for anxiety, depression and pain. Here we investigated whether perinatal exposure to URB597, a fatty acid amide hydrolase inhibitor, alters brain development and affects behaviour in adult mice. Experimental ApproachMouse dams were treated daily from gestational day 10.5 to 16.5 with 1, 3 or 10mgkg(-1) URB597. MS was used to measure a panel of endocannabinoids and related lipid compounds and brain development was assessed at embryonic day 16.5. Separate cohorts of mouse dams were treated with 10mgkg(-1) URB597, from gestational day 10.5 to postnatal day 7, and the adult offspring were assessed with a battery of behavioural tests. Key ResultsPerinatal URB597 exposure elevated anandamide and related N-acyl amides. URB597 did not induce signs of toxicity or affect dam weight gain, neurogenesis or axonal development at embryonic day 16.5. It did lead to subtle behavioural deficits in adult offspring, manifested by reduced cocaine-conditioned preference, increased depressive behaviours and impaired working memory. Anxiety levels, motor function and sensory-motor gating were not significantly altered. Conclusions and ImplicationsTaken together, the present results highlight how exposure to elevated levels of anandamide and related N-acyl amides during brain development can lead to subtle alterations in behaviour in adulthood. Linked ArticlesThis article is part of a themed section on Cannabinoids 2013. To view the other articles in this section visit
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据